These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Vijapurkar U; Kim MS; Koland JG Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161 [TBL] [Abstract][Full Text] [Related]
5. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028 [TBL] [Abstract][Full Text] [Related]
6. Orchestration of ErbB3 signaling through heterointeractions and homointeractions. McCabe Pryor M; Steinkamp MP; Halasz AM; Chen Y; Yang S; Smith MS; Zahoransky-Kohalmi G; Swift M; Xu XP; Hanein D; Volkmann N; Lidke DS; Edwards JS; Wilson BS Mol Biol Cell; 2015 Nov; 26(22):4109-23. PubMed ID: 26378253 [TBL] [Abstract][Full Text] [Related]
7. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway. Awasthi S; Hamburger AW J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179 [TBL] [Abstract][Full Text] [Related]
8. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. Lund CV; Popkov M; Magnenat L; Barbas CF Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884 [TBL] [Abstract][Full Text] [Related]
9. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein. Takahashi M; Hasegawa Y; Ikeda Y; Wada Y; Tajiri M; Ariki S; Takamiya R; Nishitani C; Araki M; Yamaguchi Y; Taniguchi N; Kuroki Y J Biol Chem; 2013 Nov; 288(46):32910-21. PubMed ID: 24097984 [TBL] [Abstract][Full Text] [Related]
10. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633 [TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Shin DH; Jo JY; Han JY Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202 [TBL] [Abstract][Full Text] [Related]
12. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564 [TBL] [Abstract][Full Text] [Related]
13. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656 [TBL] [Abstract][Full Text] [Related]
14. Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2. Kawano S; Ikeda W; Kishimoto M; Ogita H; Takai Y J Biol Chem; 2009 Aug; 284(35):23793-805. PubMed ID: 19561085 [TBL] [Abstract][Full Text] [Related]
15. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners. Li Z; Mei Y; Liu X; Zhou M Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839 [TBL] [Abstract][Full Text] [Related]
16. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407 [TBL] [Abstract][Full Text] [Related]
17. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557 [TBL] [Abstract][Full Text] [Related]
18. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116 [TBL] [Abstract][Full Text] [Related]
19. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin. Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073 [TBL] [Abstract][Full Text] [Related]
20. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]